Table 3. Treatment-related adverse events during the second induction period.

	Nivolumab followed by ipilimumab (n=58)			Ipilimumab followed by nivolumab (n=53)
	Grade 1–2	Grade 3	Grade 4	Grade 1–2	Grade 3	Grade 4
Increased ALT	8 (14%)	6 (10%)	1 (2%)	12 (23%)	1 (2%)	0
Increased AST	8 (14%)	5 (9%)	0	12 (23%)	1 (2%)	0
Increased lipase	6 (10%)	1 (2%)	0	9 (17%)	4 (8%)	1 (2%)
Increased amylase	5 (9%)	0	0	7 (13%)	2 (4%)	0
Increased blood alkaline phosphatase	4 (7%)	2 (3%)	0	2 (4%)	0	0
Decreased lymphocyte count	1 (2%)	1 (2%)	0	1 (2%)	0	0
Increased blood creatinine	0	1 (2%)	0	0	0	0
Increased hepatic enzyme	0	0	1 (2%)	0	0	0
Pruritus	16 (28%)	1 (2%)	0	5 (9%)	0	0
Rash	14 (24%)	2 (3%)	0	5 (9%)	1 (2%)	0
Rash (maculopapular)	6 (10%)	1 (2%)	0	4 (8%)	1 (2%)	0
Dermatitis (exfoliative)	0	1 (2%)	0	0	0	0
Diarrhoea	17 (29%)	7 (12%)	0	9 (17%)	1 (2%)	0
Nausea	13 (22%)	2 (3%)	0	2 (4%)	0	0
Colitis	1 (2%)	9 (16%)	0	0	5 (10%)	0
Vomiting	4 (7%)	2 (3%)	0	4 (8%)	0	0
Abdominal pain	4 (7%)	1 (2%)	0	3 (6%)	0	0
Crohn's disease	0	1 (2%)	0	0	0	0
Enterocolitis	0	0	0	0	1 (2%)	0
Fatigue	20 (34%)	1 (2%)	0	11 (21%)	3 (6%)	0
Pyrexia	10 (17%)	0	0	1 (2%)	0	0
Headache	8 (14%)	2 (3%)	0	4 (8%)	1 (2%)	0
Hypothyroidism	7 (12%)	0	0	5 (9%)	0	0
Hypophysitis	4 (7%)	0	0	1 (2%)	2 (4%)	0
Adrenal insufficiency	1 (2%)	1 (2%)	0	1 (2%)	0	0
Decreased appetite	7 (12%)	0	0	4 (8%)	1 (2%)	0
Dehydration	2 (3%)	1 (2%)	0	1 (2%)	1 (2%)	0
Polydipsia	0	0	0	0	1 (2%)	0
Muscular weakness	2 (3%)	1 (2%)	0	1 (2%)	0	0
Respiratory failure	0	0	1 (2%)	0	0	0
Hepatitis	0	3 (5%)	0	0	0	0
Hepatotoxicity	0	0	1 (2%)	0	0	0
Autoimmune disorder	0	1 (2%)	0	0	0	0
Acute kidney injury	0	1 (2%)	0	0	0	0
Renal failure	0	0	1 (2%)	0	0	0
Hypotension	0	1 (2%)	0	0	0	0

Data are n (%). ALT=alanine aminotransferase. AST=aspartate aminotransferase. No treatment-related deaths were recorded.